Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $657K | $7.76M | $10.7M | $84.7M | $130K | $61.0K | $36.0K |
| Revenue growth | — | 1080.5% | 37.3% | 695.1% | -99.8% | -53.1% | -41.0% |
| Operating income | -$102M | -$212M | -$215M | -$187M | -$247M | -$359M | -$269M |
| Operating margin | -15538.7% | -2732.6% | -2016.7% | -220.9% | -190006.2% | -588123.0% | -748344.4% |
| Net income | -$129M | -$204M | -$250M | -$183M | -$235M | -$343M | -$274M |
| Net margin | -19692.1% | -2636.3% | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (diluted) | -$24.04 | -$15.69 | -$1.84 | -$0.74 | -$18.70 | -$26.23 | -$16.06 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $39.5M | -$161M | -$126M | -$170M | -$164M | -$162M | -$150M |
| Capital expenditures | $16.0M | $51.5M | $65.5M | $24.3M | $2.69M | $464K | $780K |
| Free cash flow | $23.4M | -$212M | -$192M | -$194M | -$166M | -$163M | -$151M |
| Share buybacks | $185K | $11.8M | $0.00 | $0.00 | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $96.7M | $140M | $294M | $124M | $146M | $106M | $60.2M |
| Total assets | — | $908M | $1.13B | $938M | $750M | $491M | $340M |
| Total liabilities | — | $190M | $198M | $104M | $95.1M | $108M | $91.8M |
| Shareholders' equity | -$111M | -$293M | $930M | $833M | $655M | $383M | $248M |
| Retained earnings | — | -$334M | -$584M | -$767M | -$1.00B | -$1.35B | -$1.62B |
| Shares (wtd avg diluted) | 5.43B | 13.3M | 136M | 247M | 12.5M | 13.1M | 17.1M |
Every figure is extracted from Lyell Immunopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.